中国伤残医学
中國傷殘醫學
중국상잔의학
CHINESE JOURNAL OF TRAUMA AND DISABILITY MEDICINE
2014年
23期
18-20
,共3页
龚耀%殷晓娟%刘长龙%沈守平%刘晨
龔耀%慇曉娟%劉長龍%瀋守平%劉晨
공요%은효연%류장룡%침수평%류신
卵巢癌%腹腔积液%多西他赛%腹腔灌注化疗
卵巢癌%腹腔積液%多西他賽%腹腔灌註化療
란소암%복강적액%다서타새%복강관주화료
Ovarian cancer%Ascite%Docetaxel%Intraperitoneal chemotherapy
目的：观察多西他赛腹腔灌注治疗卵巢癌恶性腹腔积液的近期临床疗效和毒副反应。方法：2009年9月～2012年9月我院临床诊断的卵巢癌伴恶性腹腔积液的患者随机分为实验组和对照组，实验组采用静脉和腹腔同时用药方法，其方案为多西他赛37．5mg ／m2静脉滴注，同时多西他赛37．5mg ／m2腹腔灌注，顺铂20mg ／m2静脉滴注第1～5天，对照组全部采用静脉用药方法，药物种类与剂量同实验组，21天重复，每例患者完成4周期，至少2个周期。治疗结束后对2组近期临床效果、毒副反应进行评价。结果：入组37例卵巢癌恶性腹腔积液患者，其中实验组18例，对照组19例，治疗前2组患者临床特征具有均衡性（ P＞0．05）。实验组PR 11例（61．11％，11／18）优于对照组5例（26．32％，5／19），差异有统计学意义（P＝0．033＜0．05），客观缓解率（RR）即CR＋PR 83．33％（15／18）优于对照组（31．58％，6／19），差异有统计学意义（P＝0．001＜0．05）。临床受益率（CR ＋PR＋SD）优于对照组（94．44％vs 73．68）。毒副反应方面骨髓抑制、恶心呕吐、腹痛、腹泻、肌肉关节痛、肝功能异常等，2组无显著性差异（ P ＞0．05）。结论：多西他赛腹腔灌注治疗卵巢癌恶性腹腔积液的疗效和安全性较好，在临床中值得推广应用。
目的：觀察多西他賽腹腔灌註治療卵巢癌噁性腹腔積液的近期臨床療效和毒副反應。方法：2009年9月～2012年9月我院臨床診斷的卵巢癌伴噁性腹腔積液的患者隨機分為實驗組和對照組，實驗組採用靜脈和腹腔同時用藥方法，其方案為多西他賽37．5mg ／m2靜脈滴註，同時多西他賽37．5mg ／m2腹腔灌註，順鉑20mg ／m2靜脈滴註第1～5天，對照組全部採用靜脈用藥方法，藥物種類與劑量同實驗組，21天重複，每例患者完成4週期，至少2箇週期。治療結束後對2組近期臨床效果、毒副反應進行評價。結果：入組37例卵巢癌噁性腹腔積液患者，其中實驗組18例，對照組19例，治療前2組患者臨床特徵具有均衡性（ P＞0．05）。實驗組PR 11例（61．11％，11／18）優于對照組5例（26．32％，5／19），差異有統計學意義（P＝0．033＜0．05），客觀緩解率（RR）即CR＋PR 83．33％（15／18）優于對照組（31．58％，6／19），差異有統計學意義（P＝0．001＜0．05）。臨床受益率（CR ＋PR＋SD）優于對照組（94．44％vs 73．68）。毒副反應方麵骨髓抑製、噁心嘔吐、腹痛、腹瀉、肌肉關節痛、肝功能異常等，2組無顯著性差異（ P ＞0．05）。結論：多西他賽腹腔灌註治療卵巢癌噁性腹腔積液的療效和安全性較好，在臨床中值得推廣應用。
목적：관찰다서타새복강관주치료란소암악성복강적액적근기림상료효화독부반응。방법：2009년9월～2012년9월아원림상진단적란소암반악성복강적액적환자수궤분위실험조화대조조，실험조채용정맥화복강동시용약방법，기방안위다서타새37．5mg ／m2정맥적주，동시다서타새37．5mg ／m2복강관주，순박20mg ／m2정맥적주제1～5천，대조조전부채용정맥용약방법，약물충류여제량동실험조，21천중복，매례환자완성4주기，지소2개주기。치료결속후대2조근기림상효과、독부반응진행평개。결과：입조37례란소암악성복강적액환자，기중실험조18례，대조조19례，치료전2조환자림상특정구유균형성（ P＞0．05）。실험조PR 11례（61．11％，11／18）우우대조조5례（26．32％，5／19），차이유통계학의의（P＝0．033＜0．05），객관완해솔（RR）즉CR＋PR 83．33％（15／18）우우대조조（31．58％，6／19），차이유통계학의의（P＝0．001＜0．05）。림상수익솔（CR ＋PR＋SD）우우대조조（94．44％vs 73．68）。독부반응방면골수억제、악심구토、복통、복사、기육관절통、간공능이상등，2조무현저성차이（ P ＞0．05）。결론：다서타새복강관주치료란소암악성복강적액적료효화안전성교호，재림상중치득추엄응용。
Objective:To evaluate the curative effect and adverse reaction of the treatment of malignant ascites in ovarian cancer with docetaxel through intraperitoneal perfusion .Methods:All clinically patients with malignant ascites of ovarian cancer were recruited from September 1.2009 to September 1.2012 in the seventh division hospital of Xinjiang corps .The patients were randomly divided into two groups.The experimental group received Docetaxel 37.5mg /m2 via intraperitoneal and intravenous infusion on day l ,DDP 20 mg /m2 in-travenous infusion on day 1 to 5.The control group received the same regimen ,but all drugs were administrated via intravenous infusion . 21 days repeat , Each patient was received four cycles , at least two cycles chemotherapy .Evaluation of two groups of recent clinical effect and adverse reaction .Results:A total of 37 clinically patients with malignant ascites of ovarian cancer in which the experimental group (18 cases) and control group (19 cases).The clinical characteristics were well -balancedly matched with each other between two groups be-fore chemotherapy(P>0.05).Experimental group PR in 11 cases (61.11%, 11/18) is better than that of control group 5 cases (26. 32%, 5/19).There was significant difference between two groups (P =0.033 <0.05).The objective response rate (CR +PR) is 83.33%(15/18) is better than that of control group (31.58%, 6/19).There was significant difference between two groups (P =0. 001 <0.05).Clinical benefit rate (CR +PR+SD) is better than that of control group (94.44%vs 73.68).Major adverse reactions in the two groups included bone marrow restraint ,nausea and vomiting,abdominal pain,diarrhea,joint and muscle pain,Abnormal liver function, which were all tolerable ( P>0.05) .Conclusion:Docetaxel is effective and relatively safe to treat malignant ascites of ovarian cancer.It can be popularized in clinical .
